Standards of Practice in Transarterial Radioembolization

Complications (minor/major) A minor complication is a treatment-related adverse event requiring no or minimal therapy with or without overnight hospitalization for observation. A major complication is a treatment-related adverse event requiring further therapy, increased level of care, or prolonged hospitalization [11]. Lung Shunting Fraction (LSF) LSF is the percentage shunt fraction of radioactive-labeled microspheres from liver to lung. Postradioemblization Syndrome (PRS) PRS is any constellation of symptoms, including fatigue, low-grade fever, nausea and vomiting, abdominal discomfort, and malaise occurring shortly after RE. Radiation-Induced Liver Disease (RILD) RILD comprises mostly anicteric, nonmalignant ascites and elevation of alkaline phosphatase level of at least twice the upper normal level within 4 months after treatment. Technical Success Technical success is the ability to access the appropriate segments of the liver and to perform the treatment according to protocol.

[1]  H. Amthauer,et al.  Hepatic Toxicity After Radioembolization of the Liver Using 90Y-Microspheres: Sequential Lobar Versus Whole Liver Approach , 2012, CardioVascular and Interventional Radiology.

[2]  O. Solheim.  [Treatment of patients with advanced cancer]. , 1973, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[3]  D. Eschelman,et al.  Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. , 2011, AJR. American journal of roentgenology.

[4]  M. Mulcahy,et al.  Incidence of Radiation Pneumonitis After Hepatic Intra-Arterial Radiotherapy With Yttrium-90 Microspheres Assuming Uniform Lung Distribution , 2008, American journal of clinical oncology.

[5]  J. Juni,et al.  Effects of hepatic arterial yttrium 90 glass microspheres in dogs , 1988, Cancer.

[6]  S. Nag,et al.  Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. , 2009, International journal of radiation oncology, biology, physics.

[7]  J. F. Perry,et al.  Treatment of patients with advanced cancer utilizing Y90 microspheres , 1965, Cancer.

[8]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[9]  A. Benson,et al.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. , 2011, Gastroenterology.

[10]  M. Reiser,et al.  Radioembolization of Symptomatic, Unresectable Neuroendocrine Hepatic Metastases Using Yttrium-90 Microspheres , 2012, CardioVascular and Interventional Radiology.

[11]  C. Nutting,et al.  Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. , 2006, International journal of radiation oncology, biology, physics.

[12]  A. Benson,et al.  Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. , 2010, Gastroenterology.

[13]  A. Benson,et al.  Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. , 2007, International journal of radiation oncology, biology, physics.

[14]  N. Obuchowski,et al.  Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. , 2011, Journal of vascular and interventional radiology : JVIR.

[15]  S. Houle,et al.  A phase I dose escalation trial of yttrium‐90 microspheres in the treatment of primary hepatocellular carcinoma , 1992, Cancer.

[16]  R. Salem,et al.  Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. , 2012, Journal of vascular and interventional radiology : JVIR.

[17]  Daniel Normolle,et al.  Analysis of radiation-induced liver disease using the Lyman NTCP model. , 2002, International journal of radiation oncology, biology, physics.

[18]  D. Morris,et al.  Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases , 2008, Cancer.

[19]  C. Kuhl,et al.  The Significance of 99mTc-MAA SPECT/CT Liver Perfusion Imaging in Treatment Planning for 90Y-Microsphere Selective Internal Radiation Treatment , 2010, The Journal of Nuclear Medicine.

[20]  A. Benson,et al.  90Y Radioembolization for Metastatic Neuroendocrine Liver Tumors: Preliminary Results From a Multi-institutional Experience , 2008, Annals of surgery.

[21]  C. Nutting,et al.  Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. , 2007, International journal of radiation oncology, biology, physics.

[22]  J. Ertle,et al.  Radioembolization with yttrium‐90 glass microspheres in hepatocellular carcinoma: European experience on safety and long‐term survival , 2010, Hepatology.

[23]  Ariel Im,et al.  The treatment of cancer metastases in the lung by means of radiating microspheres. , 1966 .

[24]  R. Goldberg,et al.  TREATMENT OF METASTATIC COLORECTAL CANCER Review of recent advances , 2005 .

[25]  C. Nutting,et al.  Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients , 2008, American journal of clinical oncology.

[26]  D. Morris,et al.  Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases , 2010, The British journal of surgery.

[27]  R. Murthy,et al.  Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. , 2007, Journal of vascular and interventional radiology : JVIR.

[28]  D. Sze,et al.  Research reporting standards for radioembolization of hepatic malignancies. , 2011, Journal of vascular and interventional radiology : JVIR.

[29]  Tushar C. Barot,et al.  The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  A. Benson,et al.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis , 2007, Hepatology.

[31]  R. T. Ten Haken,et al.  Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Larsimont,et al.  Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. , 2008, Clinical nuclear medicine.

[33]  Kenneth G. Thurston,et al.  Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. , 2010, Journal of vascular and interventional radiology : JVIR.

[34]  P. Aspelin,et al.  Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines , 2011, European Radiology.

[35]  I. Kamel,et al.  Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. , 2009, Journal of vascular and interventional radiology : JVIR.

[36]  J. Prieto,et al.  A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. , 2009, Hepato-gastroenterology.

[37]  R. Stubbs,et al.  SELECTIVE INTERNAL RADIATION THERAPY WITH 90Y MICROSPHERES FOR COLORECTAL LIVER METASTASES: SINGLE‐CENTRE EXPERIENCE WITH 100 PATIENTS , 2006, ANZ journal of surgery.

[38]  F. Izzo,et al.  Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases , 2010, British Journal of Cancer.

[39]  Kenneth G. Thurston,et al.  Angiographic considerations in patients undergoing liver-directed therapy. , 2005, Journal of vascular and interventional radiology : JVIR.

[40]  N. Pavlakis,et al.  Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres. , 2010, Journal of vascular and interventional radiology : JVIR.

[41]  V. Gebski,et al.  Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  M. Reiser,et al.  Radioembolization in patients with hepatic metastases from breast cancer. , 2008, Journal of vascular and interventional radiology : JVIR.

[43]  M. A. Bosch,et al.  Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis , 2009, European Radiology.

[44]  F. Izzo,et al.  Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation , 2011, Hepatology.

[45]  G. van Hazel,et al.  Randomised phase 2 trial of SIR‐Spheres® plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer , 2004, Journal of surgical oncology.

[46]  W. Gradishar,et al.  90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. , 2007, Journal of vascular and interventional radiology : JVIR.

[47]  E. Van Cutsem,et al.  Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Mulcahy,et al.  Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. , 2009, Journal of vascular and interventional radiology : JVIR.

[49]  E. Felix,et al.  Intraarterial yttrium 90 in the treatment of hepatic malignancy. , 1982, Radiology.

[50]  A. Benson,et al.  Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. , 2008, Radiology.

[51]  G. Pack,et al.  The Treatment of Cancer Metastases in the Lung by means of Radiating Microspheres* , 1966, Thoraxchirurgie und vaskulare Chirurgie.

[52]  T. Chua,et al.  Factors Predicting Response and Survival After Yttrium-90 Radioembolization of Unresectable Neuroendocrine Tumor Liver Metastases: A Critical Appraisal of 48 Cases , 2010, Annals of surgery.

[53]  T. Chua,et al.  Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases , 2011, Journal of Cancer Research and Clinical Oncology.

[54]  Donald L. Miller,et al.  Society of Interventional Radiology clinical practice guidelines. , 2009, Journal of vascular and interventional radiology : JVIR.

[55]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[56]  A. Benson,et al.  Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres , 2009, Cancer.